Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

16

Revenue 2017

Tecfidera

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Tecfidera was produced by Biogen Idec.

Biogen files Tecfidera follow-up in the US

Biogen files Tecfidera follow-up in the US Biogen is also enrolling patients a head-to-head tolerability study versus Tecfidera with data due in mid-2019. ... Just when Tecfidera might become vulnerable to generic competition isn’t yet clear.

Spinraza lifts Biogen ahead of Alzheimer’s data

Spinraza lifts Biogen ahead of Alzheimer’s data Along with a useful contribution from biosimilars, that cushioned the impact of flat sales for Biogen’s multiple sclerosis franchise, headed by Tecfidera (dimethyl fumarate), which has been hit by competition ... MS drug sales came in at $2.3bn, with

Dismay as NICE rejects Roche’s MS drug Ocrevus

Dismay as NICE rejects Roche’s MS drug Ocrevus such as Novartis’ Gilenya (fingolimod) and Biogen’s Tecfidera (dimethyl fumarate).

The good, the bad and the ugly

The good, the bad and the ugly Tecfidera (MS) and Spinraza (Spinal Muscular Atrophy) are expected to generate big sales, while Tysabril (MS and Crohn’s Disease) and Avonex (MS) are expected to see sales drop due to

Biogen cuts $217m deal for Karyopharm neurology drug

Biogen cuts $217m deal for Karyopharm neurology drug Biogen reported 2017 revenues of $12.3bn, up 15% on the prior year, thanks to gains for its multiple sclerosis drugs, particularly Tecfidera (dimethyl fumarate) and rising royalties from Ocrevus (ocrelizumab) -

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials
As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...

Infographics